CAS 1032900-25-6

Ceritinib

Description:

Ceritinib is a targeted therapy medication primarily used in the treatment of non-small cell lung cancer (NSCLC) that is characterized by anaplastic lymphoma kinase (ALK) gene rearrangements. It is classified as a kinase inhibitor, specifically designed to inhibit ALK and other related kinases, thereby disrupting cancer cell proliferation and survival. Ceritinib is administered orally and is known for its ability to penetrate the blood-brain barrier, making it effective against central nervous system metastases. The substance has a molecular formula that reflects its complex structure, which includes multiple functional groups that contribute to its pharmacological activity. Common side effects associated with ceritinib include gastrointestinal disturbances, liver enzyme elevations, and fatigue. Due to its mechanism of action, ceritinib is often considered for patients who have progressed on other ALK inhibitors, highlighting its role in personalized cancer therapy. As with any medication, monitoring for adverse effects and drug interactions is essential during treatment.

Formula: C₂₈H₃₆ClN₅O₃S

InChI: InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)

InChI key: InChIKey=VERWOWGGCGHDQE-UHFFFAOYSA-N

SMILES: N(C1=C(OC(C)C)C=C(C(C)=C1)C2CCNCC2)C=3N=C(NC4=C(S(C(C)C)(=O)=O)C=CC=C4)C(Cl)=CN3

Synonyms:

• 2,4-Pyrimidinediamine, 5-chloro-N⁴-[2-[(1-methylethyl)sulfonyl]phenyl]-N²-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-
• 5-Chloro-N4-(2-((1-Methylethyl)Sulfonyl)Phenyl)-N2-(5-Methyl-2-(1-Methylethoxy)-4-(4-Piperidinyl)Phenyl)-2,4-Pyrimidinediamine
• 5-Chloro-N⁴-[2-[(1-methylethyl)sulfonyl]phenyl]-N²-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine
• Ldk 378
• Ldk378
• Zykadia
• Ceritinib
• 2,4-Pyrimidinediamine, 5-chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-

5-chloro-2-N-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-4-N-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine

CAS: 1032900-25-6

Formula: C₂₈H₃₆ClN₅O₃S

Purity: 98%

Color and Shape: Solid

Molecular weight: 558.1351

Ref: IN-DA003ABY

LDK378

CAS: 1032900-25-6

LDK378

Purity: 98%

Molecular weight: 558.14g/mol

Ref: 54-OR1026673

Ceritinib

CAS: 1032900-25-6

Formula: C₂₈H₃₆ClN₅O₃S

Color and Shape: White To Off-White Solid

Molecular weight: 558.14

Ref: 4Z-C-267001

Ceritinib

CAS: 1032900-25-6

Ceritinib

Purity: ≥98%

Molecular weight: 558.14g/mol

Ref: 54-BUP14422

LDK378

CAS: 1032900-25-6

Ref: 7W-GW0546

Ceritinib

CAS: 1032900-25-6

Ceritinib (LDK378) is an ALK inhibitor with selective, ATP-competitive, and oral activity. Ceritinib has antitumor activity. Cost-effective and quality-assured.

Formula: C₂₈H₃₆ClN₅O₃S

Purity: 98.52% - 99.77%

Color and Shape: Solid

Molecular weight: 558.14

Ref: TM-T1791

5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine

Controlled Product

CAS: 1032900-25-6

Applications 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine, is a Anaplastic lymphoma kinase (ALK) inhibitor.
References Marsilje, T. H., et al.: J. Med. Chem., 56, 5675 (2013);

Formula: C₂₈H₃₆ClN₅O₃S

Color and Shape: Neat

Molecular weight: 558.14

Ref: TR-C367365

Ceritinib

CAS: 1032900-25-6

ALK receptor tyrosine kinase inhibitor

Formula: C₂₈H₃₆ClN₅O₃S

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 558.14 g/mol

Ref: 3D-FC61431